Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Revekka Gyftaki"'
Autor:
Revekka Gyftaki
Η θυρεοειδοτρόπος ορμόνη (TSH) ρυθμίζει την φυσιολογική λειτουργία του θυρεοειδούς αδένα, διαμέσου της σύνδεσής της με τον αντίστοιχο υπο
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c729a4194c04ebacc760029533d2f7e9
https://doi.org/10.12681/eadd/35903
https://doi.org/10.12681/eadd/35903
Autor:
Piotr J. Wysocki, Nuria Lainez, Stéphane Oudard, Aude Flechon, Gustavo Rubio, Revekka Gyftaki, Iciar Garcia Carbonero, Antoine Angelergues, Sylvestre Le Moulec, Joaquim Bellmunt, Alison Birtle, Javier Munarriz, Mustafa Ozguroglu, Aline Guillot, Eleni Efstathiou, Nicolas Delanoy, Begoña Campos Balea, Emilio Esteban, Daniel Castellano, Iria Gonzalez, P. Borrega
Publikováno v:
Clinical Genitourinary Cancer
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
instname
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
instname
Several agents have demonstrated an overall survival (OS) benefit in metastatic castration-resistant prostate cancer (mCRPC); however, optimal sequencing is unknown. Retrospective analysis of data from 574 mCRPC patients showed increasing OS with the
Autor:
John C. Araujo, Sankar N. Maity, Sumankalai Ramachandran, Eleni Efstathiou, Revekka Gyftaki, Jing Fang Lu, Christopher J. Logothetis, Mark Titus, Guanglin Wu, Elsa M. Li-Ning-Tapia
Publikováno v:
Scientific Reports
Cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1) is a validated treatment target for the treatment of metastatic castration-resistant prostate cancer (CRPC). Abiraterone acetate (AA) inhibits both 17α-hydroxylase (hydroxylase) and 17,20-lyase
Autor:
Javier Munarriz, Antoine Angelergues, Stéphane Oudard, Claire Barker, Begoña Campos Balea, Iria Gonzalez, Pablo Borrega, Alison Birtle, Aude Flechon, Mustafa Ozguroglu, Emilio Esteban, Iciar Garcia Carbonero, Daniel Castellano, Nicolas Delanoy, Nuria Lainez, Piotr J. Wysocki, Aline Guillot, Revekka Gyftaki, Sylvestre Le Moulec, Eleni Efstathiou
Publikováno v:
Journal of Clinical Oncology. 35:267-267
267 Background: Optimal sequencing of new androgen-receptor targeted agents (ART) abiraterone and enzalutamide with docetaxel (DOC) and cabazitaxel (CABA) is unknown. In this large retrospective cohort of mCRPC patients (pts) treated with CABA after
Autor:
Revekka, Gyftaki, Gyftaki, Revekka, Christina, Liacos, Liacos, Christina, Ekaterini, Politi, Politi, Ekaterini, Michalis, Liontos, Liontos, Michalis, Katerina, Saltiki, Saltiki, Katerina, Theocharis, Papageorgiou, Papageorgiou, Theocharis, Nikolaos, Thomakos, Thomakos, Nikolaos, Dimitrios, Haidopoulos, Haidopoulos, Dimitrios, Alexandros, Rodolakis, Rodolakis, Alexandros, Maria, Alevizaki, Alevizaki, Maria, Aristotelis, Bamias, Bamias, Aristotelis, Athanasios, Dimopoulos, Dimopoulos Meletios, Athanasios
Publikováno v:
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 24(5)
ObjectiveThyroid-stimulating hormone (TSH) regulates normal thyroid function by binding to its receptor (thyroid-stimulating hormone receptor -TSHR) that is expressed at the surface of thyroid cells. Recently, it has been demonstrated that TSHR is ab
Objective: Thyroid-stimulating hormone (TSH) regulates normal thyroid function by binding to its receptor (thyroid-stimulating hormone receptor -TSHR) that is expressed at the surface of thyroid cells. Recently, it has been demonstrated that TSHR is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0a291a86031415eafa53b5c9cc9489fc
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3161927
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3161927
Autor:
S. Le Moulec, Aline Guillot, Nicolas Delanoy, D. Stefanou, Emilio Esteban, Aude Flechon, Revekka Gyftaki, Iria Gonzalez, B. Campos Balea, Mustafa Ozguroglu, Daniel Castellano, Javier Munarriz, Stéphane Oudard, Antoine Angelergues, Eleni Efstathiou, Joaquim Bellmunt, A. Ardavanis
Publikováno v:
European Journal of Cancer. 51:S488
Autor:
Aude Flechon, Aline Guillot, Eleni Efstathiou, Stéphane Oudard, Javier Munarriz, B. Campos Balea, Mustafa Ozguroglu, Revekka Gyftaki, S. Le Moulec, Antoine Angelergues, Nicolas Delanoy, Joaquim Bellmunt, Emilio Esteban, Alexandros Ardavanis, Daniel Castellano, D. Stefanou, Iria Gonzalez
Publikováno v:
European Journal of Cancer. 51:S489
Autor:
Eftychia Kafantari, Evangelos Bournakis, Aristotelis Bamias, Eleni Efstathiou, Efthimios Kostouros, Meletios A. Dimopoulos, Revekka Gyftaki
Publikováno v:
Journal of Clinical Oncology. 32:e16096-e16096
e16096 Background: platinum based therapy is a potentially valid choice for heavily pretreated mCRPC patients (pts) whose disease progresses with anaplastic features. Methods: This is a retrospecti...
Autor:
Meletios-Athanasios Dimopoulos, Aristotle Bamias, Revekka Gyftaki, C. Liakos, Argyrios Ziogas, Marinos L. Tsiatas
Publikováno v:
Journal of Clinical Oncology. 26:16505-16505
16505 Background: We have shown that CD4+CD25+ Tregs and CD3+CD56+ NK-like T cells are significantly increased in the ascites from ovarian cancer compared with ascites from cirrhosis or blood from ...